Aoxing Pharmaceutical Comp. Inc. (AOXG)

[corncakes0]

New website in the making!!!! June 23 shareholder meeting!!!! Oxy approval around the corner folks!!

[JacquesStrap]

sorry wrong board

[PennyWorld]

Can you please expand on that thought?

[JacquesStrap]

thoughts on buying more preferred at this point in hope the 128/64 offer goes through.

[PennyWorld]

The tax sellers in Dec won't be buying back today due to the 30 day IRS wash rule, so these must be bottom pickers. No news. Todays vol was 2x the 21 average vol.... show new interest.

[JJSeabrook]

63,747 shares went off at the .86 ask. Nice buy!

AXN

[JJSeabrook]

Nice bounce to .865. No news.

[PennyWorld]

Year-end tax selling EOM

[PennyWorld]

IMO what is holding this stock down is:

1) dilution of shares by the company. Raising $ to restructure their high interest debt. While this will help clean up their financial statements (to some extent) the dilution will also adversely impact future EPS reports. Expect more dilution.

2) the recent law suit injects a level of uncertainty

[bullrider2]

AXN needs to increase its share volume.

[JJSeabrook]

Aoxing Pharma Announces Opening Of Government Funded Drug Research Center
PR Newswire Aoxing Pharmaceutical Company, Inc.
2 hours ago

????

JERSEY CITY, N.J., Dec. 4, 2015 /PRNewswire/ -- Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced the inauguration of its new Narcotic and Psychotropic Drug Research Center. Construction of the Center was funded by the Reform and Development Commission of Hebei Province in China along with Aoxing Pharma's Chinese subsidiary, with a total investment of US$2.15 million.

This state-of-the art Research Center occupies 2200m2, and meets current GLP and GMP standards. The Center will provide facilities for narcotic and psychotropic drug research and development, including chemical synthesis, transdermal patch formulation, pilot manufacturing, quality review and analytical labs. The Center is outfitted with the latest technology, to offer an optimal research environment to the research scientists at Aoxing Pharma.

"We are delighted by the inauguration of the new R&D Center, and are honored to receive this powerful endorsement by the Chinese government," said Mr. Zhenjiang Yue, the Chairman and CEO of Aoxing Pharma. "The government contributed to the funding of this project in recognition of our company's strong commitment to the narcotic drug and psychiatric treatment business. Government endorsement of our efforts can also be seen in our recent receipt of authorization from the China FDA (CFDA) to initiate four drug programs, including Lorcaserin Hydrochloride tablets and Lorcaserin Hydrochloride API (active pharmaceutical ingredient), weight-reduction drugs for overweight and obese patients, as well as Caffeine tablets (for swallowing) and Caffeine buccal tablets (for dissolving in the mouth), for the management of mental fatigue and headache. With government approval and our new government-funded research facility, we are well positioned to quickly introduce such products into the Chinese pharmaceutical market."

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China Food and Drug Administration ("CFDA"). For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.

Certain statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. All forward-looking statements included herein are based upon information available to the Company as of the date hereof and, except as is expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. To the extent that any statements made here are not historical, these statements are essentially forward-looking. Undue reliance should not be placed on forward-looking information. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, specifically, Item 1A, "Risk Factors," in the Form 10-K for the year ended June 30, 2015, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aoxing-pharma-announces-opening-of-government-funded-drug-research-center-300188105.html

[willlbone]

Come on baby. Take out those stop/loss under a dollar.

[weezywallbanger]

Let's go baby lets rise.

[$Pistol Pete$]

$AXN Daily & Weekly Chart

[color=green]

[color=green]

[PennyWorld]

it needs some pumping via a PR or elsewhere, else we wait for the next earnings report. PPS growth is all about the news.

[Zaadx]

Why is it still dropping? Another bounce off $1.20 I presume.

[JJSeabrook]

AXN Revs up 92%, EPS $.02, Revs $8.74M, Net $1.35M

[$Pistol Pete$]

$AXN Daily & Weekly Chart

[color=green]

[color=green]

[ospreyeye]

thanks bud - looking for a close above the middle BB for the bull signal & possible start of a new up trend -

[$Pistol Pete$]

$AXN nice analysis

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118394439

[ospreyeye]

$AXN Chart from yesterday – bullish intraday move above the middle Bollinger Band @ 1.35 – key level to close above & turn into support – when the middle BB turns into support a new up trend can begin – EMA 4 bull crossed EMA 8 – volume spike – MACD bull cross – RSI hitting the bull zone – Fast STO hitting the overbought/power zone –

[$Pistol Pete$]

$AXN Daily Chart For Review

[deri21]

JERSEY CITY, NJ / ACCESSWIRE / November 4, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced that one of its products, Xiongju Shangqing Tablet, has been included in the government essential drug procurement lists for nine Chinese provinces: Shanghai, Qinghai, Gansu, Hubei, Shanxi, Anhui, Sichuan, Jilin and Inner Mongolia. The combined population of these nine provinces is approximately 400 million, representing a significant potential market.

The Xiongju Shangqing Tablet is indicated for treatment of migraine, toothache and sore throat, as well as flu-related pain, fever and runny nose. Hebei Aoxing, the operating subsidiary of Aoxing Pharma, is one of only three pharmaceutical companies licensed to produce the Xiongju Shangqing Tablet in China.

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China Food and Drug Administration ("CFDA"). For more information, please visit: www.aoxingpharma.com.

[Namaste Charting]

In @ $1.47 $AXN

[$Pistol Pete$]

$AXN Daily & Weekly Chart

[Lone Wolf]

Well...today's looking great !!

[crudeoil24]

Company diluting shares to pay themselves, expenses, etc. No dividends here for investors as well. It is all in the SEC filings.

[JJSeabrook]

Don't see any filings or PR to warrant the sudden drop. I thought maybe they announced a big private placement but I see nada!

[JJSeabrook]

WOW! Just dropped to $1.33.

[JJSeabrook]

Gap got filled. Maybe she'll have a good afternoon.

[JJSeabrook]

AXN Announces Fiscal 2015 Net Income of $5.8 Million vs. $8.6 Million Net Loss in Fiscal 2014

Company Doubles Revenue and Achieves First Profitable Year Since Inception in 2002; Live Conference Call at 8:30 AM Today; Access Instructions Below
Marketwired Aoxing Pharmaceutical Company, Inc.
4 hours ago

????

JERSEY CITY, NJ--(Marketwired - Oct 13, 2015) - Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) today announced that, for the year ended June 30, 2015, the company doubled revenue to $25,481,199, compared to $12,739,371 in revenue for fiscal 2014.

The company recorded net income from operations in fiscal 2015 of $8,695,657 versus a loss of $3,334,879 in the prior year. After accounting for interest expense of $5,768,094 and a tax benefit of $2,704,369, Aoxing had net income in fiscal 2015 of $5,818,473, or $.09 per share. This compares to a net loss of $8,634,380, or $(.16) per share, in fiscal 2014.

Weighted average number of shares outstanding at June 30, 2015 was 63,107,104 compared to 49,856,247 at June 30, 2014.

The doubling of revenue over the prior fiscal year was primarily the result of Aoxing eliminating most third-party distributors during fiscal 2015, enabling the company to expand its sales team and sell its products directly to the end customer -- including large chain drug stores -- at higher prices.

Aoxing's fiscal 2015 performance was also boosted by a sharp decrease in the market prices of raw materials, which resulted in a lower year-over-year aggregate on cost of goods sold. As a result of this decrease, Aoxing's gross margin in fiscal 2015 increased to 77.7% from 45.6% in fiscal 2014, resulting in a gross profit of $19,792,236, a 240% increase from $5,813,674 in the prior year.

The company's profitability in fiscal 2015 was further enhanced by a 23.8% decrease in general and administrative expenses and a 40.8% decrease in research and development expenses when compared to fiscal 2014.

Aoxing's cash balance as of June 30, 2015 was $5,371,545, compared to $2,329,660 as of June 30, 2014. This increase was the result of cash flow generated by the company's operating profit and sale of common stock, partially offset by repayment of loans and capital expenditures during the year.

Mr. Zhenjiang Yue, Chairman and CEO of Aoxing Pharma, said, "We are proud to have achieved strong results in fiscal 2015 -- our first profitable year -- and believe fiscal 2016 will also be a very strong year.

"As reported in September 2015, the company's lead product, Zhongtongan, was included in the government essential drug procurement lists for Hebei, Jiangsu, Shanxi, and Hubei Provinces. This event," said Mr. Yue, "along with Aoxing's plans to obtain additional provincial essential drug procurement listings for the product and to collaborate with new distribution companies for Zhongtongan, should result in substantial increases in sales of the product in fiscal 2016.

"Also in September, Aoxing entered into an agreement with Shijiazhuang Zhongtian Medical Company, a pharmaceutical products distributor in China, that will enable our Hebei Aoxing subsidiary to initiate production of 84 over-the-counter pill medicines it acquired in 2008. This agreement is expected to yield about $5 million in revenue in fiscal 2016.

"Third," noted Mr. Yue, "the company's Tilidine HCL pain fighting tablets, approved for sale in June 2015 by the China FDA (CFDA) and scheduled for market introduction in the fourth calendar quarter of 2015, should realize substantial market growth by end of June 2016, and be granted a minimum of eight-year market exclusivity protection within China."

The CEO added that Aoxing has submitted an NDA to the CFDA for final production clearance of the company's Oxycodone/Acetaminophen Tablets and Capsules used to treat acute and chronic pain, and expects such clearance will be received in fiscal 2016. When received, Aoxing would become the first Chinese company to produce this generic product.

Also, in July of 2015 AXN announced positive results of clinical trials for its Buprenorphine/Naloxone sublingual tablets as a treatment for opioid dependence. The company is currently working on submitting this clinical data to the CFDA, and expects to receive indications on this approval in the near future.

"With this diversification of our product line, as well as our entry in the narcotic product sector -- a sector as yet underdeveloped in China -- we are expecting fiscal 2016 revenue to increase substantially, to about $45 million," said Mr. Yue.

He added that he expected the company's clinical trial expenses in fiscal 2016 to be "minimal," thus helping Aoxing to maintain a strong bottom line for the year.

The company invites all interested parties to join its live Fiscal 2015 Earnings Conference Call at 8:30 am EDT this morning. Participants may dial 877-407-0778 in the U.S. or 201-689-8565 internationally, five to ten minutes before the beginning of the call. The call will also be webcast at http://www.investorcalendar.com/IC/CEPage.asp?ID=172955 and on the Aoxing website (http://www.aoxingpharma.com).

About the Company
Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China Food and Drug Administration ("CFDA"). For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

http://finance.yahoo.com/news/aoxing-pharma-announces-fiscal-2015-110000553.html

[crudeoil24]

May run later or tomorrow. Overall healthy upside this year. Love the charts!

[KingDMC]

Hopped in $1.60 for quick trade hopefully. Got a tight stop not too far.

[crudeoil24]

Company notes in SEC filings.

[bullrider2]

So Crude, why is the big dumps. Could it be possible some profit taking. I see more like diluting rather than shareholders taking profits. AXN went as high as $2.02 before the market open today.

[crudeoil24]

Up 391% this year! > This company has done a 180 degree turn.

[bullrider2]

Seen like this is beginning to turn into dump city. Glad I traded it before the market opening.

[bullrider2]

Great revenue earnings. Moderate o/s.

[crudeoil24]

( AXN ) Aoxing Pharmaceutical Company to Host Live Conference Call and Webcast on Tuesday, October 13, 2015, 8:30am EDT
23 hours 26 minutes ago - DJNF

JERSEY CITY, NJ / ACCESSWIRE / October 12, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT:AXN) today said it will host a live conference call and webcast at 8:30am EDT on Tuesday, October 13, 2015. The call will immediately follow the announcement of Aoxing's fiscal (June 30) 2015 financial results.

[crudeoil24]

Could be looking @ multi-day runner. CC @ 8:30EST

[Lone Wolf]

That earnings report is phenomenal to say the least. Company predicting an even better 2016. Rare gem these days.

$AXN

[crudeoil24]

AXN is a great $$$$$ opportunity.

[Lone Wolf]

77% gross margins. $19.8 mil gross profits! Damn.

[bullrider2]

I hope the buyout go thru.

[JJSeabrook]

Aoxing Pharma to Announce Fiscal 2015 Financial Results, Host Webcast and Conference Call Oct. 13 at 8:30 AM Eastern
Accesswire
2 hours ago

????

JERSEY CITY, NJ / ACCESSWIRE / October 2, 2015 / Aoxing Pharmaceutical Company, Inc. (AXN), a leading China-based pain management company, today said it would announce financial results for its fiscal year 2015, ended June 30, 2015 at 8:30 a.m. Eastern time on Tuesday, October 13, and immediately follow this announcement with a conference call chaired by the company's chairman and chief executive officer, Mr. Zhenjiang Yue, and chief financial officer Mr. Wilfred Chow.

The call will be accessible on the company's website, www.aoxingpharma.com, and via phone conference. Directions for both will be announced prior to the call.

During the call Mr. Chow will discuss Aoxing's performance during fiscal 2015 and the company's plans to grow its core traditional Chinese medicine business as well as develop its new narcotic medicine division in fiscal 2016. Messrs. Yue and Chow will then answer investor questions.

All interested investors are invited to participate in this call.

About the Company

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China Food and Drug Administration ("CFDA"). For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

CONTACT:

Aoxing Pharmaceutical Company:
646-367-1747
[e-mail]

or

Asia IR•PR
Jimmy Caplan, 512-329-9505
[e-mail]

or

Media Relations:
Asia IR•PR
Rick Eisenberg, 212-496-6828
[e-mail]

SOURCE: Aoxing Pharmaceutical Company, Inc

[JJSeabrook]

I saw a couple posters called IR and were told that ER & projections will come out on 10/14.

AXN

[JJSeabrook]

They filed an NT 10-K so ER, and projections, probably not until 10/15. AXN

[onthelak42]

http://www.capitalcube.com/blog/index.php/aoxing-pharmaceutical-co-inc-breached-its-50-day-moving-average-in-a-bullish-manner-september-23-2015/
*Disclaimer : This is as of previous day’s closing price.Technical IndicatorsBelow is a quick look at 5 technical indicators for Aoxing Pharmaceutical Co., Inc.. More studies are available on the Technical Chart.IndicatorSignalClosing Price above/below 50 Day Moving AverageBullishClosing Price above/below 200 Day Moving AverageBullish50 Day Moving Average above/below 200 Day Moving AverageBullishRSI Reading Level (70)N/AMACD […]
(Read more...) The post Aoxing Pharmaceutical Co., Inc. breached its 50 day moving average in a Bullish Manner : September 23, 2015 appeared first on CapitalCube.

[JJSeabrook]

AXN ER was 6:07 a.m. last year. Probably premarket again this year.

[JJSeabrook]

AXN ER was Monday, 9/29 last year. Chances are it will be Monday, 9/28 this year.

That's also what this site shows, but guessing it's based upon the same reasoning. https://www.earningswhispers.com/stocks/axn